Zimmer Biomet Holdings, Inc. · Healthcare · Medical Devices
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$94.32
+$2.55 (+2.77%) 11:14 AM ET
Prev closePrevC$91.77
OpenOpen$93.30
Day highHigh$94.84
Day lowLow$93.24
VolumeVol420,764
Avg volAvgVol2,095,252
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$17.50B
EV/Sales
2.89
P/E ratio
21.70
FY Revenue
$8.51B
EPS
4.23
Gross Margin
69.87%
Div yield
1.08%
Sector
Healthcare
AI report sections
MIXED
ZBH
Zimmer Biomet Holdings, Inc.
No AI report section text found yet for this symbol.
AI summarized at 4:06 PM ET, 2026-10-12
AI summary scores
INTRADAY:75SWING:53LONG:55
Volume vs average
Intraday (cumulative)
+53% (Above avg)
Vol/Avg: 1.53×
RSI
48.81(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.06 (Weak)
MACD: -0.11 Signal: -0.05
Short-Term
+0.40 (Strong)
MACD: -1.19 Signal: -1.59
Long-Term
-0.01 (Weak)
MACD: -1.47 Signal: -1.46
Intraday trend score
67.36
LOW55.54HIGH69.00
Latest news
ZBH•12 articles•Positive: 10Neutral: 2Negative: 0
PositiveZacks Investment Research• Na
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Zimmer Biomet (ZBH) is identified as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company trades at a P/E ratio of 11.98, below its industry average of 15.93, and demonstrates solid valuation metrics across P/B and P/CF ratios, suggesting it may be undervalued relative to its earnings outlook.
ZBH receives a Zacks Rank #2 (Buy) with an 'A' Value grade. Multiple valuation metrics (P/E of 11.98 vs. industry 15.93, P/B of 1.58 vs. industry 2.35, P/CF of 10.65 vs. industry 13.02) indicate the stock is trading below industry averages, suggesting undervaluation. Combined with strong earnings outlook, the analysis presents ZBH as an attractive value investment opportunity.
PositiveZacks Investment Research• Na
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet (ZBH), a musculoskeletal healthcare company, has been identified as a #2 (Buy) on the Zacks Rank with a VGM Score of B and Value Style Score of A. The company features attractive valuation metrics with a forward P/E ratio of 10.51, and analysts have revised earnings estimates higher, with the consensus estimate at $8.54 per share and an average earnings surprise of +4.5%.
ZBH received a #2 (Buy) Zacks Rank rating with strong Style Scores (VGM Score of B, Value Score of A). The company has attractive valuation metrics (forward P/E of 10.51), positive analyst earnings revisions, and a solid earnings surprise history of +4.5%, indicating strong fundamentals and growth potential.
PositiveZacks Investment Research• Na
Are Investors Undervaluing Baxter International (BAX) Right Now?
Zacks highlights two Medical-Products stocks with strong value characteristics: Baxter International (BAX) and Zimmer Biomet (ZBH), both holding Zacks Rank #2 (Buy) ratings and Value grade A. Both stocks trade at attractive valuations compared to industry averages across multiple metrics including P/E, PEG, P/B, and P/S ratios, suggesting they are currently undervalued with strong earnings outlooks.
BAXZBHvalue investingstock valuationmedical productsearnings estimatesP/E ratioPEG ratio
Sentiment note
ZBH also holds Zacks Rank #2 (Buy) and Value grade A. Forward P/E of 11.98 and PEG of 2.25 compare favorably to industry averages of 15.71 and 1.88 respectively. P/B ratio of 1.58 vs industry 2.30 indicates attractive valuation.
NeutralZacks Investment Research• Na
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.
Zimmer Biomet acquired iovera from Pacira, but the article provides no performance data or analysis regarding this acquisition's impact on the company.
Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR
The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.
MDTSYKZBHSNNAI in orthopedic surgerysurgical planningrobotic surgical systemsimplant placement
Sentiment note
Major player in the AI orthopedic surgery market with strong competitive positioning in a rapidly expanding sector driven by technological advancements.
NeutralGlobeNewswire Inc.• Researchandmarkets.Com
Surgical Navigation System Report; Patent Leadership Led by the United States with 1,204 Patents In 230-Page Patent Landscape Covering Neurosurgery, Spinal, Orthopaedic, ENT, and Dental Navigation Applications
A comprehensive patent landscape analysis of surgical navigation systems reveals 2,524 patents filed globally from 2010-2025, with the United States leading at 1,204 patents. The global market was valued at USD 8.38 billion in 2024 and is projected to reach USD 18.47 billion by 2030 at a 14% CAGR. Key drivers include AI-guided support, augmented reality, and robotic integration, with North America dominating and Asia-Pacific as the fastest-growing region. Major players include Brainlab AG, Medtronic, and Stryker.
Listed among top players in the report but with limited specific details provided regarding patent activity, partnerships, or market position compared to other featured companies.
PositiveGlobeNewswire Inc.• Sns Insider
Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider
The global wound irrigation systems market is projected to grow from USD 307.87 million in 2025 to USD 430.05 million by 2035, with a CAGR of 3.55%. Growth is driven by rising chronic wound prevalence, increased surgical volumes, and innovations in pulsatile lavage systems. North America leads with 40% market share, while Asia Pacific shows the fastest growth at 4.7% CAGR. Manual systems currently dominate with 53% market share, though battery-operated systems are expected to grow fastest.
Listed as a major player in the wound irrigation systems market, positioned to benefit from the projected market growth of 3.55% CAGR through 2035.
PositiveBenzinga• Prnewswire
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings announced that its Board of Directors approved a quarterly cash dividend of $0.24 per share for Q2 2026, payable on or about July 31, 2026 to stockholders of record as of June 25, 2026.
The company's announcement of a consistent quarterly dividend demonstrates financial stability and confidence in future cash flows. Regular dividend payments are viewed positively by investors as they indicate the company's ability to generate profits and return value to shareholders.
PositiveGlobeNewswire Inc.• Mordor Intelligence
Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor Intelligence
The global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.
ORGOIARTZBHSNNtissue engineeringregenerative medicinebiomaterialsstem cell research
Sentiment note
Major company in tissue engineering with strong positioning in orthopedics applications, one of the key growth segments mentioned in the market analysis.
PositiveGlobeNewswire Inc.• Healthcare Foresights
[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The global surgical drill bits market was valued at USD 316 million in 2025 and is projected to reach USD 540 million by 2035, growing at a CAGR of 5.5%. Growth is driven by healthcare infrastructure development in emerging economies, increased surgical procedures, and rising demand for infection prevention measures. Hospitals are expected to dominate the market segment, while North America leads in market share and Asia-Pacific shows the highest growth rate.
Major player in the surgical drill bits market with exposure to growing orthopedic and trauma surgery segments
PositiveGlobeNewswire Inc.• Delveinsight
Global Foot and Ankle Devices Market to Observe Stunning Growth at a CAGR of ~8% by 2034 | DelveInsight
The global foot and ankle devices market is projected to grow from USD 5.9 billion in 2025 to USD 9.2 billion by 2034, driven by rising incidence of foot and ankle conditions, diabetes-related complications, aging populations, and technological advancements in minimally invasive procedures and 3D-printed implants. North America leads the market, with key players including DePuy Synthes, Stryker, and Zimmer Biomet driving innovation through recent product launches and strategic developments.
JNJSYKZBHSNNfoot and ankle devicesorthopedic implantsdiabetes complicationsminimally invasive surgery
Sentiment note
Key market player with recent commercial rollout of advanced solutions for complex foot and ankle trauma (October 2025), indicating strong market presence and innovation pipeline.
PositiveGlobeNewswire Inc.• Towards Healthcare
Ambulatory Surgical Equipment Market to Reach USD 14.58 Billion, Rising at 7.85% by 2035
The global ambulatory surgical equipment market is valued at USD 7.39 billion in 2026 and is expected to reach USD 14.58 billion by 2035, growing at a 7.85% CAGR. North America dominates with 34% market share, while Asia Pacific is the fastest-growing region. Endoscopy and laparoscopy systems lead by product type at 18% share, with compact intraoperative imaging expected to grow fastest. Independent ambulatory surgical centers account for 42% of the market.
Listed as a key player with exposure to orthopedic equipment demand in the growing ambulatory surgical equipment market.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal